PMV Pharmaceuticals

Update in progress

PMVP (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

PMV Pharmaceuticals, Inc. is a precision oncology company focused on discovering and developing small molecule therapies for p53 mutations and other p53-related cancers in the United States. It is advancing rezatapopt, a selective structural corrector for p53 Y220C mutations, in Phase 2 trials for tumor-agnostic diseases. Formerly PJ Pharmaceuticals, the company renamed PMV in July 2013. It was incorporated in 2013 and is headquartered in Princeton, New Jersey.

Company score

Sentiment: 0.14; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.46; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.24; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.19; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.17; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive

Company

MarketNasdaqGS (NMS)
LocationUnited States
CEODr. David H. Mack Ph.D.
Founded2013
Employees54
Websitewww.pmvpharma.com

Identifiers

ISINUS69353Y1038
FIGIBBG007NM47G3
CUSIP69353Y103
CIK0001699382